Champignon Brands (CSE: SHRM) (OTC: SHRMF) (FWB: 496),
a human optimization sciences company focused on applying novel and natural
treatment protocols to address a broad range of disorders and deficiencies with
an emphasis on psychedelic medicine, today announced continued augmentation of
its Special Advisory Committee with the addition of key individuals experienced
in highly regulated industries primed for rapid growth. To this accord, the
Company announced the appointment of Jay Kheita, ACPR, to its Special Advisory
Committee, where he will help lead the integration of Champignon’s novel and
natural treatment protocols into its existing consumer packaged goods (“CPGs”)
portfolio. Khetia holds pharmacy licenses in Canada, Australia and England and
an honors degree in pharmacy specializing in pharmacognosy, the study of
medicinal plants, from the University of Brighton. He is also a founder of
AltMed Capital Corp., a leading Canadian psychedelic medicine clinic operator,
IP aggregator and solutions provider, and is currently a clinical advisor at
the Leslie Dan faculty of pharmacy at the University of Toronto. “We are
pleased to welcome Jay to Champignon’s Special Advisory Committee, where he
will function as a cornerstone advisor throughout our pursuit to develop and
deploy precision medicine focused formulations and delivery systems,” Champignon
CEO Gareth Birdsall stated in the news release.
To view the full press release, visit http://ibn.fm/qtmit
About Champignon Brands Inc.
Champignon Brands Inc. is a research-driven company
specializing in the formulation of a suite of medicinal mushrooms health
products, as well as novel ketamine, anaesthetics and adaptogenic delivery
platforms for the nutritional, wellness and alternative medicine industries.
Via its vertically integrated alternative medicine product range, Champignon is
pursuing the development and commercialization of rapid onset treatments
capable of improving health outcomes, such as depression and post-traumatic
stress disorder (“PTSD”), as well as substance and alcohol use disorders. Under
a collaborative research agreement with the University of Miami’s Miller School
of Medicine, the Company is conducting pre-clinical studies and eventual human
clinical trials, with the objective of demonstrating safety and efficacy of the
combination of psilocybin and cannabidiol in treating mTBI with PTSD or
stand-alone PTSD. Champignon continues to be inspired by sustainability, as its
medicinal mushroom-infused SKUs are organic, non-GMO and vegan certified. For
more information, visit the Company’s website at www.Champignonbrands.com.
NOTE TO INVESTORS: The latest news and updates
relating to SHRM are available in the company’s newsroom at http://ibn.fm/SHRM
About QualityStocksNewsBreaks
QualityStocksNewsBreaks provide
a rapid summary of corporate news that catch the attention of QualityStocks.
QualityStocksBreaks are designed to keep investors up to date on important and
breaking news in the small-cap and micro-cap markets. Spanning all industries,
including energy, entertainment, telecommunications, healthcare, retail and more,
these news breaks deliver opportunities the investment community may have
missed. Whether it is earnings results, mergers and acquisitions, or any other
market-moving news, our news breaks keep you in the know. QualityStocks is
committed to connecting subscribers with companies that have huge potential to
succeed in the short and long-term future. It is part of our mission statement
to help the investment community discover emerging companies that offer
excellent growth potential.
QualityStocks (QS)
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Scottsdale, Arizona
www.QualityStocks.com
480.374.1336 Office
Editor@QualityStocks.com
Please see full terms of use and disclaimers on the
QualityStocks website applicable to all content provided by QS, wherever
published or re-republished: http://www.qualitystocks.net/disclaimer.php
No comments:
Post a Comment